Robert A. Bradway

Chairman, CEO, and President at AMGEN

Board

Since 2012

Age

62 years

Education

Holds a bachelor's degree in Biology from Amherst College and a master's degree in Business Administration from Harvard Business School.

Tenure

Joined AMGN in 2006 as Vice President, Operations Strategy, then served as Executive Vice President and CFO (2007-2010), President and Chief Operating Officer (2010-2012), and has been CEO since 2012 and Chairman since 2013.

Also at AMGEN

DMR

David M. Reese

EVP and Chief Technology Officer

Derek Miller

SVP, Human Resources

Esteban Santos

EVP, Operations

About

Robert A. Bradway is a seasoned executive with a strong foundation in both science and finance. Prior to his tenure at AMGN, he honed his expertise in the financial industry, notably serving as a Managing Director at Morgan Stanley in London from 2001, which laid the groundwork for his strategic and operational insights.

During his time at AMGN, he has consistently driven strategic growth and operational excellence through successive leadership roles. His transition from Vice President, Operations Strategy to key executive positions such as CFO, COO, President, and ultimately CEO underscores a career marked by progressive responsibility and impactful decision-making.

Beyond his direct contributions at AMGN, his involvement as a board member for prestigious companies—such as The Boeing Company—and his participation in academic and governance bodies highlight a broader commitment to corporate leadership and public policy. This multifaceted experience not only strengthens his executive profile but also reinforces his reputation as a leader who bridges the worlds of biotechnology, finance, and governance.

$AMGN Performance Under Robert A. Bradway

Past Roles

Organization	Role	Date Range	Details
Amgen	President and Chief Operating Officer	2010–2012	Held prior to becoming Chairman, CEO, and President
Amgen	Executive Vice President and Chief Financial Officer	2007–2010	Served as CFO before further promotion
Amgen	Vice President, Operations Strategy	2006	Early leadership role at Amgen
Morgan Stanley (London)	Managing Director	Starting in 2001	Oversaw the banking department and corporate finance activities in Europe before joining Amgen

External Roles

Organization	Role	Date Range	Details
The Boeing Company	Director	Since 2016	Chair of the Finance Committee and member of the Governance and Public Policy Committee
University of Southern California (USC)	Trustee	Since 2014	Serves on the board of trustees

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,786,977	Bi-weekly	Fixed base salary earned each bi-weekly pay period before pre-tax contributions
All Other Compensation	$680,456	Annually	Comprises Perquisites (Total: $189,811 : Company aircraft $56,692, car & driver $6,155, financial planning $15,000, other $111,964), Retirement Contributions (401(k): $33,000 and SRP: $457,645 ), and Other Expenses (HSR Act Fee: $100,000, Charitable Contributions: $10,000; Executive physicals not specified)

Performance Compensation

Data from FY 2023

Performance Units (Plan-Based Awards)

Metric/Detail	Value/Details
Performance Metrics & Weights	EPS (50%) and ROIC (50%)
TSR Modifier	±30% adjustment based on TSR ranking relative to S&P 500: +30% if at/above 75th percentile; -30% if at/below 25th percentile; 0% at 50th percentile; linear interpolation in between
Payout Range	30% to 200% of target payout (operating measures range from 30% to 170% + TSR modifier)
Vesting Schedule	Vests at the end of the three-year performance period – December 31, 2025
Evaluation Period	January 1, 2023 to December 31, 2025
Grant Date	May 2, 2023
Grant Date Fair Value	Total fair value of $7,956,212; per unit fair value $252.49
Grant Date Stock Price	$235.97 per share
Additional Details	Dividend equivalents accrue and are payable in shares if the performance units are earned; awards align executive incentives with company performance

Non-Equity Incentive Plan Awards (EIP/GMIP)

Metric/Detail	Value/Details
Performance Metrics & Weights	Financial and operating goals: Deliver Results (60%) – split as Revenue (30%) and Non-GAAP Net Income (30%); Innovative Pipeline (30%); Annual Priorities (10%)
Composite Score (2023)	159.3%
Target Payout	$2,676,669
Maximum Payout	$6,022,505
Actual Payout (2023)	$4,264,000 based on the composite score
Grant Date	March 6, 2023
Grant Date Fair Value	$7,956,212 for performance units and $3,182,291 for RSUs
Grant Date Stock Price	$235.97 per share
Additional Details	No explicit thresholds; payout is determined by achieving pre-established operating and financial targets

These details for 2023 summarize the performance compensation components awarded to Robert A. Bradway. The performance units and non-equity incentive awards are structured to align executive rewards with company financial and operational performance, incorporating strict vesting schedules, precise evaluation periods, and adjustments based on market performance (TSR modifier).